ACXP earnings date and last-quarter result: next report 2026-08-14, last quarter beat, P/E -0.30. Updated 2026-07-23.
Acurx Pharmaceuticals (ACXP) Research Hub
Acurx Pharmaceuticals (ACXP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.09 USD (-3.96%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.30, market cap 0.00B. This hub links to the full technical, earnings and options research available for ACXP.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.09 USD (-3.96%) |
| 52-week range | 1.07 USD – 1.88 USD |
| Trend regime | Range |
| 14-day RSI | 23.8 (Oversold) |
| Trailing P/E | -0.30 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for ACXP
Covered Call on ACXP: how it works, illustrative setup around the real 1.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACXP: how it works, illustrative setup around the real 1.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACXP: how it works, illustrative setup around the real 1.09 USD price, max profit/loss, breakeven and when to use it. Educational.
ACXP technical analysis: range, last 1.09 USD, RSI 23.8, 52w range 1.07 USD–1.88 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ACXP in?
Acurx Pharmaceuticals (ACXP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACXP in an uptrend or downtrend?
As of 2026-10-26, ACXP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACXP's trailing P/E ratio?
ACXP's trailing P/E is -0.30, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ACXP next report earnings?
ACXP is next scheduled to report earnings on 2026-08-14.